Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice